Gynecologic Cancers

Chicago, IL—The addition of the PD-1 inhibitor pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) resulted in a substantial and clinically meaningful improvement in overall survival (OS) in patients with persistent, recurrent, or metastatic cervical cancer, according to the final OS analysis of the phase 3 KEYNOTE-826 trial. Read More ›

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between April 13, 2021, and May 21, 2021. Read More ›

Encourage Minority Patients with Ovarian Cancer to Participate in Clinical Trials

“Compared to those not enrolled in clinical trials, the evidence shows that the minority patients participating in clinical trials had increased overall survival,” said Khilen B. Patel, MD, at the 2018 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Read More ›

Angiogenesis is an active area of clinical research in ovarian cancer, but proving that this approach extends overall survival (OS) has been somewhat challenging thus far. Read More ›

Neoadjuvant chemotherapy was found equivalent to primary surgery followed by chemotherapy for patients with advanced ovarian cancer in the Medical Research Council Chemotherapy Or Upfront Surgery (MRC CHORUS) trial reported at the 2013 American Society of Clinical Oncology Annual Meeting. Read More ›

A list of resources arranged and provided for patients, survivors, providers, researchers and supporters in the field of Oncology. Read More ›

Previous trials of maintenance therapy for patients with ovarian cancer have failed to show improved survival. A study presented at the 2013 American Society of Clinical Oncology Annual Meeting is the first successful phase 3 trial in this setting—targeted therapy pazopanib extended progression-free survival (PFS) in women with ovarian cancer by a median of 5.6 months. Read More ›

T-DM1 was the first antibody-drug conjugate to gain US Food and Drug Administration approval for HER2 (human epidermal growth factor 2)-positive metastatic breast cancer. Read More ›

According to a retrospective review of more than 13,000 cases, most women with ovarian cancer received substandard care that significantly reduced their survival odds. Read More ›

Each year, more than 2 million Americans face a new diagnosis of skin cancer. Some 50,000 patients receive a diagnosis of melanoma. Regular skin checks, however, can assist in discovering melanoma at its earliest stages.

Read More ›

Page 1 of 2

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: